Lucid Diagnostics to join industry forum on oncology diagnostics

Lucid Diagnostics Inc. announced that it will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York City on November 11, 2026. CEO Lishan Aklog is scheduled to join a panel discussion regarding the reimbursement roadmap for emerging oncology diagnostics.

The event serves as a platform for industry executives to engage with investors. In addition to the panel, Aklog and CFO Dennis McGrath will hold individual meetings with institutional investors to discuss the company’s diagnostic technology.

A subsidiary of PAVmed Inc., Lucid Diagnostics specializes in tools for the early detection of esophageal precancer. The company’s primary focus remains addressing the clinical needs of patients diagnosed with gastroesophageal reflux disease, or chronic heartburn, who are at elevated risk for esophageal cancer.